These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15757941)

  • 21. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of the burden of prior authorization of psychotherapeutics (BoPAP) scale to assess the effects of prior authorization among Texas Medicaid providers.
    Brown CM; Nwokeji E; Rascati KL; Zachry W; Phillips GA
    Adm Policy Ment Health; 2009 Jul; 36(4):278-87. PubMed ID: 19350379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of conventional antipsychotic medications for patients with schizophrenia in a medicaid population: therapeutic and cost outcomes over 2 years.
    McCombs JS; Luo M; Johnstone BM; Shi L
    Value Health; 2000; 3(3):222-31. PubMed ID: 16464186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
    Marcus SC; Olfson M
    Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spillover effects of state medicaid antipsychotic prior authorization policies in US commercially insured youth.
    Spence O; Reeves G; dosReis S
    Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1064-1071. PubMed ID: 32558177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential effect of early or late implementation of prior authorization policies on the use of Cox II inhibitors.
    Roughead EE; Zhang F; Ross-Degnan D; Soumerai S
    Med Care; 2006 Apr; 44(4):378-82. PubMed ID: 16565640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of outcomes associated with restricted access to atypical antipsychotics.
    Rajagopalan K; Hassan M; Boswell K; Sarnes E; Meyer K; Grossman F
    Am J Manag Care; 2016 Jun; 22(6):e208-14. PubMed ID: 27355908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medicaid prior authorization and controlled-release oxycodone.
    Morden NE; Zerzan JT; Rue TC; Heagerty PJ; Roughead EE; Soumerai SB; Ross-Degnan D; Sullivan SD
    Med Care; 2008 Jun; 46(6):573-80. PubMed ID: 18520311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of prior authorization policies on medicaid-enrolled children's use of antipsychotic medications: evidence from two mid-Atlantic states.
    Stein BD; Leckman-Westin E; Okeke E; Scharf DM; Sorbero M; Chen Q; Chor KH; Finnerty M; Wisdom JP
    J Child Adolesc Psychopharmacol; 2014 Sep; 24(7):374-81. PubMed ID: 25144909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving mental health treatments through comparative effectiveness research.
    Wang PS; Ulbricht CM; Schoenbaum M
    Health Aff (Millwood); 2009; 28(3):783-91. PubMed ID: 19414887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness.
    Lu CY; Soumerai SB; Ross-Degnan D; Zhang F; Adams AS
    Med Care; 2010 Jan; 48(1):4-9. PubMed ID: 19956079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmaceuticals: pharmaceutical cost controls--2005. End of Year Issue Brief.
    Seay M; Varma P
    Issue Brief Health Policy Track Serv; 2005 Dec; ():1-20. PubMed ID: 16708455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Medicaid prior authorization on angiotensin-receptor blockers: can policy promote rational prescribing?
    Fischer MA; Choudhry NK; Winkelmayer WC
    Health Aff (Millwood); 2007; 26(3):800-7. PubMed ID: 17485759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population.
    Eaddy M; Grogg A; Locklear J
    Clin Ther; 2005 Feb; 27(2):263-72. PubMed ID: 15811492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting medication costs and usage: expenditures in a juvenile detention facility.
    Tennyson DH
    J Correct Health Care; 2009 Apr; 15(2):98-104; quiz 159. PubMed ID: 19477814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medicaid prior authorization policies and imprisonment among patients with schizophrenia.
    Goldman D; Fastenau J; Dirani R; Helland E; Joyce G; Conrad R; Lakdawalla D
    Am J Manag Care; 2014 Jul; 20(7):577-86. PubMed ID: 25295404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medicaid cost control measures aimed at second-generation antipsychotics led to less use of all antipsychotics.
    Vogt WB; Joyce G; Xia J; Dirani R; Wan G; Goldman DP
    Health Aff (Millwood); 2011 Dec; 30(12):2346-54. PubMed ID: 22147863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Do drug formulary policies reflect evidence of value?
    Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trends in prescription drug expenditures by Medicaid enrollees.
    Banthin JS; Miller GE
    Med Care; 2006 May; 44(5 Suppl):I27-35. PubMed ID: 16625061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.